@article{fd8658b3c98d4e20a3031e3f7ebd397f,
title = "The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris",
abstract = "Background: Although hidradenitis suppurativa (HS) shares some transcriptomic and cellular infiltrate features with psoriasis, their skin proteome remains unknown. Objective: To define and compare inflammatory protein biomarkers of HS and psoriasis skin. Methods: We assessed 92 inflammatory biomarkers in HS (n = 13), psoriasis (n = 11), and control skin (n = 11) using Olink high-throughput proteomics. We also correlated HS skin and blood biomarkers using proteomics and RNA sequencing. Results: We identified 57 differentially expressed proteins (DEPs) in lesional psoriasis and 64 DEPs in lesional HS skin, compared to healthy controls. Both HS and psoriasis lesional skin demonstrated a significant upregulation of T helper 1 and T helper 17 proteins. Healthy-appearing perilesional HS skin had 63 DEPs compared to healthy controls. Nonlesional HS and psoriasis skin had 24 and 7 DEPs, respectively, compared to healthy controls. Tumor necrosis factor and 8 other proteins were significantly correlated with clinical severity in perilesional HS skin (2 cm from a nodule). Limitations: Inclusion of only moderate-to-severe patients and the cohort size. Conclusion: HS has a greater inflammatory profile and is more diffusely distributed compared with psoriasis. Proteins correlated with disease severity are potential disease mediators. Perilesional skin is comparably inflamed to lesional skin, suggesting the need to treat beyond skin nodules.",
keywords = "Olink proteomics, biomarkers, hidradenitis suppurativa, inflammation, lesional, nonlesional, perilesional, psoriasis",
author = "Kristina Navrazhina and Sandra Garcet and Frew, {John W.} and Xiuzhong Zheng and Israel Coats and Emma Guttman-Yassky and Krueger, {James G.}",
note = "Funding Information: Dr Krueger has received research support (grants paid to the institution) from AbbVie, Amgen, BMS, Boehringer, EMD Serono, Innovaderm, Kineta, LEO Pharma, Novan, Novartis, Paraxel, Pfizer, Regeneron, and Vitae and personal fees from AbbVie, Acros, Allergan, Aurigne, BiogenIdec, Boehringer, Escalier, Janssen, Lilly, Novartis, Pfizer, Roche, and Valeant. Dr Guttman-Yassaky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, Medimmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB, and is a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, LEO Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. Authors Navrazhina, Zheng, and Coats and Drs Garcet and Frew have no relevant conflicts of interest to declare. Funding Information: Funding sources: Author Navrazhina was supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM007739 to the Weill Cornell /Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program. Drs Frew and Krueger were supported in part by grant # UL1 TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. Dr Frew was supported by the Shapiro-Silverberg Fund for the Advancement of Translational Research and the Hidradenitis Suppurativa Foundation Danby Grant. Publisher Copyright: {\textcopyright} 2021 American Academy of Dermatology, Inc.",
year = "2022",
month = feb,
doi = "10.1016/j.jaad.2021.07.035",
language = "English",
volume = "86",
pages = "322--330",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",
}